Endometrial Cancer Clinical Trials (as of August 2, 2021) ENGOT-en15/MITO Leading group: MITO Clinical Trial Study: GOG-F/Merck phase 3 endometrial cancer trial in MSI-H population: pembro vs carbo-paclitaxel Planned number of patients: TBA Participating groups: TBA Planned start in 3Q 2021 ENGOT-en14/DGOG/RAINBO Leading group: DGOG Clinical Trial Study: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, the RAINBO plateform trial Planned number of patients: differs from cohorts TP53: 420; MSI: 300, NSMP: 600, POLE : 100 Participating groups: GINECO, NCRI, CCTG ENGOT-en13/GINECO/DOMENICA Leading group: GINECO Clinical Trial Study: Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced/metastatic setting Planned number of patients: 142 Participating groups: BGOG, GEICO, MaNGO, MITO Planned start in 4Q 2021 ENGOT-en12/NOGGO/INCYTE Leading group: NOGGO Clinical Trial Study: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) Planned number of patients: 220 Participating groups: BGOG, GINECO, HECOG, MITO ENGOT-en11/BGOG/KEYNOTE-B21 Leading group: BGOG Clinical Trial Study: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without (Chemo)Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Carcinoma After Surgery With Curative Intent Planned number of patients: 990 Participating groups: A-AGO, AGO, CEEGOG, GEICO, GINECO, HECOG, ISGO, PGOG, TRSGO, MITO, NCRI, NSGO ENGOT-en10/BGOG/DUO-E Leading group: BGOG Clinical Trial Study: A Phase 3 trial with Durvalumab-Olaparib in newly diagnosed advanced and recurrent endometrial cancer Planned number of patients: 699 Participating groups: NOGGO, HECOG, ISGO, PGOG, NSGO, CEEGOG ENGOT-en8/GINECO/ROCSAN Leading group: GINECO Clinical Trial Study: ROCSAN study: A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy Planned number of patients: 63 in phase 1, 170 in phase 2 Participating groups: AGO, GEICO, MITO Planned start in 3Q 2019 ENGOT-en7/MaNGO/atTEnd Leading group: MaNGO Clinical Trial Study: AtTEnd trial: Phase III double-blind randomized placebo controlled trial of Atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer Planned number of patients: 550 Participating groups: GEICO, SAKK, A-AGO, AGO, NCRI, JGOG, ANZGOG, TGOG, KGOG FPI October 2018 ENGOT-en6/NSGO/RUBY (Part II) Leading group: NSGO Clinical Trial Study: A phase III, randomized, open-label study of TSR-042, an Anti-PD-1 monoclonal antibody, versus investigator´s choice chemotherapy in patients with advanced/recurrent endometrial cancer Planned number of patients: 270 Participating groups: BGOG, CEEGOG, DGOG, ISGO ENGOT-en5/BGOG-en5/SIENDO Leading group: BGOG Clinical Trial Study: A randomized phase III trial of maintenance with Selinexor/placebo after combination chemotherapy for patients with advanced or reccurent endometrial cancer Planned number of patients: 192 Participating groups: CEEGOG, GEICO, MITO, NOGGO, ISGO Next ENGOT meeting ENGOT General Assembly October 6-7, 2022 Berlin, Germany Directly to: ESGO Annual Congress ESGO‘s Journal latest articles myESGO ESGO Newsletter Get notified on all news and activities right in your mailbox. Sign-up Now! You May Also Like GCA WORKSHOPS Watch the Webcasts Read More CLINICAL TRIALS Latest Published Research Read More FOR PATIENTS Key Insights Read More ESGO MEETING ESGO Congress 2022 Read More